Results 91 to 100 of about 34,135 (204)

Molecular and genomic advances in breast cancer: A comprehensive review of predictive and therapeutic innovations

Precision Medical Sciences, EarlyView.
Breast cancer subtypes, estrogen receptor‐positive (ER+), HER2‐enriched, and TNBC, are defined by genomic and epigenetic signatures. Multi‐omics profiling, immunotherapy, liquid biopsy, and AI‐driven radiogenomics enable precision medicine. Tools like Oncotype DX and PAM50 support personalized care.
Samina Malik, Arif Malik, Shahzad Ahmad, Hassan Mohsin, Shazia Iqbal   +4 more
wiley   +1 more source

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin [PDF]

, 2016
This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al.Recent preclinical evidence has suggested that Ewing Sarcoma (ES) bearing EWSR1-ETS fusions could be particularly sensitive to PARP inhibitors
Amaral, Ana Teresa, Fraile, Susana, García-Macías, Carmen, Herrero-Martín, David, Mora, Jaume, Ordóñez, José Luis, San-Segundo, Laura, Sevillano, Victoria, Teodosio, Cristina, Tirado, Óscar M., Álava, Enrique de   +10 more
core   +1 more source

Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Acute myeloid leukaemia (AML) is an aggressive disease with poor survival and high relapse rates. Coupled with the complex mutational burden observed, there is an unmet clinical need for more targeted therapies. Epigenetic therapies have shown promise both as monotherapy and in combination strategies and specifically histone lysine demethylase,
Laura Monaghan, Roderick P. Bunschoten, Joana Bittencourt‐Silvestre, Taeju Park, Susan Gannon, Petrisor Alin Pirvan, Alex Hoose, Helen Wheadon, Robert M. J. Liskamp, Xu Huang, Heather G. Jørgensen   +10 more
wiley   +1 more source

EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma [PDF]

, 2018
Many cancer types are driven by oncogenic transcription factors that have been difficult to drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers.
Abraham, Brian J., Alexe, Gabriela, Benes, Cyril H., Chowdhury, Dipanjan, Conway, Amy Saur, Dharia, Neekesh V., Gray, Nathanael S., Iniguez, Amanda Balboni, Kalev, Peter, Kwiatkowski, Nicholas, Leggett, Alan, Mora, Jaume, Stegmaier, Kimberly, Stolte, Björn, Wang, Emily Jue, Young, Richard A, Zhang, Tinghu   +16 more
core   +1 more source

Synergistic RU486 and olaparib therapy enhances apoptosis in endometriosis by simultaneously targeting hormonal signalling and DNA repair

British Journal of Pharmacology, EarlyView.
Background and Purpose Endometriosis is a chronic, hormone‐dependent disorder characterized by ectopic implantation of endometrial tissue, often accompanied by pain and infertility. Although the progesterone receptor modulator RU486 is effective for pain relief, its impact on lesion regression is limited, possibly due to apoptosis resistance and ...
Yujie Peng, Meng Zhang, Libo Zhu, Wenqiang Qian, Jingjing Yan, Huidi Jiang, Yu Xin, Ying Zhang, Dongli Sun, Weidong Fei, Mengdan Zhao   +10 more
wiley   +1 more source

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease [PDF]

, 2016
HIGHLIGHTS: Leptomeningeal disease occurs more commonly in BRCA-mutated ovarian cancer; A clinically significant dose of olaprib is able to penetrate the leptomeninges; Leptomeningeal metastases in a BRCA-mutated ovarian cancer responded to ...
Bangham, M, Goldstein, R, Ledermann, JA, Walton, H   +3 more
core   +1 more source

FOLFIRINOX vs. Gemcitabine/Nab‐Paclitaxel for Pancreatic Cancer by BRCA2 and TMB Status: A Japanese C‐CAT Database Study

Cancer Science, EarlyView.
In a large real‐world C‐CAT cohort of unresectable or recurrent pancreatic cancer, we evaluated outcomes with first‐line FOLFIRINOX versus gemcitabine/nab‐paclitaxel by BRCA2 pathogenic variant and TMB status. Survival was more strongly associated with therapeutic sequencing than the initial regimen, supporting early molecular profiling to optimize the
Kazuyuki Mizuno, Takuya Ishikawa, Takanori Ito, Yuko Takano, Osamu Maeda, Hiroki Kawashima, Yuichi Ando   +6 more
wiley   +1 more source

A ribose-functionalized NAD+ with unexpected high activity and selectivity for protein poly-ADP-ribosylation. [PDF]

, 2019
Nicotinamide adenine dinucleotide (NAD+)-dependent ADP-ribosylation plays important roles in physiology and pathophysiology. It has been challenging to study this key type of enzymatic post-translational modification in particular for protein poly-ADP ...
Chen, Jingwen, Cheng, Qinqin, Dai, Zhefu, Evdokimov, Nikolai M, Lam, Albert T, Louie, Stan G, Lu, Yanran, Pei, Hua, Zhang, Xiao-Nan, Zhang, Yong   +9 more
core   +1 more source

Automodification of N‐terminal serine residues facilitates PARP2 release from DNA

The FEBS Journal, EarlyView.
PARP2 is involved in detecting DNA damage and its N‐terminal role is largely unknown. Based on biochemical and biophysical data, our findings suggest that in the presence of HPF1, N‐terminal serine 8 and 73 are enriched in auto‐ADP‐ribosylation. Our results provide insight into the mechanistic role of PARP2 N‐terminus in the PARylation‐dependent ...
Saurabh Singh Dhakar, Albert Galera‐Prat, Jin Cai, Julia Preisser, Tiila‐Riikka Kiema, Andreas Ladurner, Lari Lehtiö   +6 more
wiley   +1 more source

MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models [PDF]

, 2018
Targeting the DNA damage response (DDR) in tumors with defective DNA repair is a clinically successful strategy. The RAS/RAF/MEK/ERK signalling pathway is frequently deregulated in human cancers.
Crowley, L, Elenbaas, B, Estandian, A, Garcia-Gomez, JJ, Goodstai, S, Hartley, J, Hochhauser, D, Jia, R, MA, J, Rodriguez-Justo, M, Syed, S, Vena, F   +11 more
core   +1 more source